当前位置： SCI文献检索 > Clinical Breast Cancer期刊下所有文献 > Implant-sparing Mastectomy: An Alternative for Women Undergoing Mastectomy With Retropectoral Implants.

Implant-sparing Mastectomy: An Alternative for Women Undergoing Mastectomy With Retropectoral Implants.

Abstract：

INTRODUCTION:Implant-sparing mastectomy (ISM) is a skin-sparing mastectomy that preserves a retropectoral implant and potentially eliminates the need for tissue expansion or complex reconstruction. This study aimed to determine oncologic and surgical outcomes and reconstructive patterns in patients undergoing ISM. PATIENTS AND METHODS:A single-institution, retrospective review of patients undergoing ISM from 2006 to 2018 was performed. Patient/tumor characteristics, stage, adjuvant therapy use, 90-day complication rates, reconstruction type, and disease recurrence were collected. RESULTS:A total of 121 ISMs in 73 women were performed. Seventy (57.9%) ISMs were for breast cancer (BC) treatment and 51 (42.1%) for prophylaxis. Among BC cases, 72.3% were cT1/cT2 and 73.8% were cN0; 72.3% received systemic therapy and 33.8% received radiation therapy. There were 3 deaths owing to BC at the median follow-up of 35 months. Among 5 recurrences, only 1 was local. There was no BC identified after prophylactic ISM. Total 90-day complication rate per ISM was 15.7%. Rates were 0.8% for both seroma and wound infection, 2.5% for wound dehiscence, 3.3% for hematoma, and 8.2% for skin necrosis. The majority (72.6%) of patients required only implant exchange for reconstruction. Overall use of autologous reconstruction was low (12.3%); 77.8% of flaps were performed in patients receiving radiation therapy. CONCLUSION:ISM is a unique approach for patients pursuing mastectomy for BC treatment or prevention with equivalent oncologic outcomes and complication rates to mastectomy with reconstruction. Reconstruction for the majority was markedly simplified by elimination of tissue expansion while maintaining a low rate of flap reconstruction.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Burke EE,Laronga C,Sun W,DeBiase S,Naqvi SMH,Fridley B,Czerniecki BJ,Hoover SJ,Khakpour N,Kiluk JV,Lee MC

doi

10.1016/j.clbc.2019.08.007

subject

Has Abstract

pub_date

2020-02-01 00:00:00

pages

e14-e19

issue

1

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(19)30666-4

journal_volume

20

pub_type

杂志文章

相关文献

Clinical Breast Cancer文献大全
  • Aromatase inhibitors for the treatment and prevention of breast cancer.

    abstract：:In a review of current information on aromatase inhibitors (AIs) and their use in breast cancer treatment and prevention, published reports were obtained through a Medline search. Tamoxifen, a selective estrogen receptor modulator, is approved for use in metastatic breast cancer (MBC), the adjuvant treatment of breast...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2005.n.006

    authors： Kalidas M,Brown P

    更新日期：2005-04-01 00:00:00

  • Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy: A Propensity Score Analysis and Predictors of Care for Patients With Brain Metastases From Breast Cancer.

    abstract：BACKGROUND:Metastases to the brain occur in 10%-16% of patients with breast cancer, with incidence reportedly increasing. Historically, brain metastases (BM) have been treated with whole-brain radiation therapy (WBRT), but stereotactic radiosurgery (SRS) is an increasingly favored treatment option. In this study we use...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.11.001

    authors： Mainwaring W,Bowers J,Pham N,Pezzi T,Shukla M,Bonnen M,Ludwig M

    更新日期：2019-04-01 00:00:00

  • A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.

    abstract：BACKGROUND:The purpose of this study was to investigate whether combining pembrolizumab with palliative radiation therapy (RT) improves outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). PATIENTS AND METHODS:Eligible patients had HR+/human epidermal growth factor receptor 2-negat...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.01.012

    authors： Barroso-Sousa R,Krop IE,Trippa L,Tan-Wasielewski Z,Li T,Osmani W,Andrews C,Dillon D,Richardson ET 3rd,Pastorello RG,Winer EP,Mittendorf EA,Bellon JR,Schoenfeld JD,Tolaney SM

    更新日期：2020-06-01 00:00:00

  • Dietary Patterns and Risk of Invasive Ductal and Lobular Breast Carcinomas: A Systematic Review and Meta-analysis.

    abstract：:The histopathologic subtypes of breast cancer, including invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), differ in terms of risk factors, progression, and response to treatment. The PubMed/Medline, Web of Science, and Scopus databases were searched up to February 2020 for published studies on the...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2020.03.007

    authors： Dianatinasab M,Rezaian M,HaghighatNezad E,Bagheri-Hosseinabadi Z,Amanat S,Rezaeian S,Masoudi A,Ghiasvand R

    更新日期：2020-08-01 00:00:00

  • Physical Exercise Positively Influences Breast Cancer Evolution.

    abstract：:Breast cancer is one of the most commonly diagnosed types of cancer in women. Its pathogenesis involves genetic, hormonal, and environmental factors. A large body of evidence indicates that physical activity has positive effects on every aspect of breast cancer evolution, including prevention, medical treatment, and a...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2017.05.003

    authors： Adraskela K,Veisaki E,Koutsilieris M,Philippou A

    更新日期：2017-10-01 00:00:00

  • Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.

    abstract：:A pilot chemoprevention study from the Royal Marsden Hospital in the United Kingdom demonstrated that tamoxifen could be administered safely to healthy women. This led to the establishment of multicenter trials, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and Italian National Cancer I...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2001.n.008

    authors： Ross PJ,Powles TJ

    更新日期：2001-04-01 00:00:00

  • BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-Analysis.

    abstract：INTRODUCTION:There is only limited data from clinical practice on the relevance of body mass index (BMI) on pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). PATIENTS AND METHODS:The impact of BMI on pCR and survival outcome was examined in 324 patients wi...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clbc.2016.02.018

    authors： Erbes T,Stickeler E,Rücker G,Buroh S,Asberger J,Dany N,Thornton S,Iborra S,Hirschfeld M,Gitsch G,Mayer S

    更新日期：2016-08-01 00:00:00

  • Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

    abstract：BACKGROUND:The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC). PATIENTS...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.09.014

    authors： Chan A,Moy B,Mansi J,Ejlertsen B,Holmes FA,Chia S,Iwata H,Gnant M,Loibl S,Barrios CH,Somali I,Smichkoska S,Martinez N,Alonso MG,Link JS,Mayer IA,Cold S,Murillo SM,Senecal F,Inoue K,Ruiz-Borrego M,Hui R,Dendulu

    更新日期：2020-10-06 00:00:00

  • Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives.

    abstract：:[18F]fluorodeoxyglucose positron emission tomography (FDG-PET) is a metabolic imaging modality that has increasing applications in oncology, neurology, and cardiology. Among the oncology applications, breast cancer is one of the most extensively studied diseases. FDG-PET has been performed for diagnosis, staging, and ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2003.s.016

    authors： Wu D,Gambhir SS

    更新日期：2003-04-01 00:00:00

  • Digital mammography: a review of technical development and clinical applications.

    abstract：:For detecting and diagnosing breast cancer at its earliest stage, mammography is the most sensitive technique currently available and is therefore the method of choice. Screen-film mammography has been used successfully as a screening test for breast cancer for > 2 decades. However, conventional mammography has substa...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2003.n.013

    authors： Shah AJ,Wang J,Yamada T,Fajardo LL

    更新日期：2003-04-01 00:00:00

  • The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

    abstract：:Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Su...

    journal_title：Clinical breast cancer

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.3816/CBC.2002.n.020

    authors： Vogel VG,Costantino JP,Wickerham DL,Cronin WM,Wolmark N

    更新日期：2002-06-01 00:00:00

  • A new technique that complements sentinel lymph node biopsy: lymph node dissection under the intercostobrachial nerves in early-stage breast cancer.

    abstract：BACKGROUND:Arm lymphedema is a common complication after axillary lymph node dissection (ALND), and there is no effective treatment. The clinical significance of sentinel lymph node biopsy (SLNB) is to avoid the risk of arm lymphedema caused by ALND in cases in which the nodes are negative for cancer cells. In develope...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2012.10.005

    authors： Li J,Jia S,Zhang W,Zhang Y,Qiu F,Xue J,Gu X

    更新日期：2013-06-01 00:00:00

  • Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

    abstract：:Despite the widespread use of trastuzumab in the management of patients with HER2-overexpressing metastatic breast cancer, its optimal duration of administration is unknown. We retrospectively reviewed the medical records of 80 such patients who received trastuzumab monotherapy or combination chemotherapy beyond disea...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/cbc.2003.n.017

    authors： Fountzilas G,Razis E,Tsavdaridis D,Karina M,Labropoulos S,Christodoulou C,Mavroudis D,Gogas H,Georgoulias V,Skarlos D

    更新日期：2003-06-01 00:00:00

  • The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.

    abstract：:Trastuzumab improves survival outcomes for patients with HER2-positive (HER2+) breast cancer, yet not all such women receive this important therapy. Trastuzumab was approved by the US Food and Drug Administration in 1998 and the European Medicines Agency in 2000 as treatment for HER2+ metastatic breast cancer (MBC). O...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2018.01.006

    authors： Blackwell K,Gligorov J,Jacobs I,Twelves C

    更新日期：2018-04-01 00:00:00

  • Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.

    abstract：PURPOSE:We investigated the efficacy and toxicity of sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in combination with vinorelbine therapy in a phase I/II trial in patients with metastatic breast cancer. PATIENTS AND METHODS:We enrolled 11 patients in the phase I po...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2013.10.013

    authors： Luu T,Frankel P,Chung C,Chow W,Mortimer J,Hurria A,Somlo G

    更新日期：2014-04-01 00:00:00

  • BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.

    abstract：BACKGROUND:The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as "BRCAness" using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.05.008

    authors： Mori H,Kubo M,Kai M,Velasquez VV,Kurata K,Yamada M,Okido M,Kuroki S,Oda Y,Nakamura M

    更新日期：2018-10-01 00:00:00

  • Adjuvant therapy in elderly patients with breast cancer.

    abstract：:The elderly population has been neglected by the traditional approach to clinical breast cancer research. Elderly women have been underrepresented in breast cancer clinical trials, with the majority of studies being restricted to patients aged < 70 years. Elderly patients frequently have comorbidities and/or impaired ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2004.n.022

    authors： Biganzoli L,Aapro M,Balducci L,Crivellari D,Minisini A,Piccart M

    更新日期：2004-08-01 00:00:00

  • Improved Performance of Adjunctive Ultrasonography After Mammography Screening for Breast Cancer Among Chinese Females.

    abstract：INTRODUCTION:Until now, no studies have investigated whether women other than those with dense breasts are suitable for adjunctive ultrasonography after negative mammography, and investigated whether all women with negative mammography are suitable for adjunctive ultrasonography. METHODS:Based on the Multi-modality In...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.07.014

    authors： Dong H,Huang Y,Song F,Dai H,Liu P,Zhu Y,Wang P,Han J,Hao X,Chen K

    更新日期：2018-06-01 00:00:00

  • Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence.

    abstract：:The perinatal period, childhood, and adolescence are important intervals for breast cancer risk development. Endogenous estrogen exposure is thought to be highest in utero, and exposure to estrogens throughout life plays an important role in increasing breast cancer risk. Some evidence suggests that breast tissue is n...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2008.n.038

    authors： Ruder EH,Dorgan JF,Kranz S,Kris-Etherton PM,Hartman TJ

    更新日期：2008-08-01 00:00:00

  • Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.

    abstract：:The androgen receptor (AR) is increasingly considered as a potential biomarker for breast cancer. Nevertheless, the prognostic value of AR expression in patients with triple negative breast cancer (TNBC) remains controversial. Therefore, in this meta-analysis, we investigated AR expression and its impact on survival o...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2020.01.002

    authors： Xu M,Yuan Y,Yan P,Jiang J,Ma P,Niu X,Ma S,Cai H,Yang K

    更新日期：2020-08-01 00:00:00

  • The Accuracy of Breast MR Imaging for Measuring the Size of a Breast Cancer: Analysis of the Histopathologic Factors.

    abstract：BACKGROUND:The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS:Eight hundred women were i...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.07.007

    authors： Choi WJ,Cha JH,Kim HH,Shin HJ,Chae EY

    更新日期：2016-12-01 00:00:00

  • Spontaneous Rib Fractures After Breast Cancer Treatment Based on Bone Scans: Comparison Of Conventional Versus Hypofractionated Radiotherapy.

    abstract：BACKGROUND:Spontaneous rib fractures (SRFs) are defined as fractures without apparent blunt force trauma. This study evaluated the incidence and risk factors of SRFs after treatment of patients with breast cancer based on bone scans. In addition, we analyzed radiation-associated SRFs and identified radiotherapy (RT) fa...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.07.009

    authors： Kim DW,Kim JS,Kim K,Shin KH

    更新日期：2020-07-23 00:00:00

  • Breast Cancer and Ovulation Induction Treatments.

    abstract：BACKGROUND:This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer. PATIENTS AND METHODS:This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Behesh...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.03.003

    authors： Taheripanah R,Balash F,Anbiaee R,Mahmoodi M,Akbari Sene A

    更新日期：2018-10-01 00:00:00

  • Synchronous carcinoma and lymphoma of the breast.

    abstract：:Primary breast lymphoma is a rare entity. Furthermore, extranodal marginal zone B-cell lymphoma affecting the breast is exceedingly rare. We report a unique case of invasive lobular carcinoma diagnosed simultaneously with an extranodal marginal zone B-cell lymphoma of the breast. A literature review demonstrated 2 rep...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2008.n.033

    authors： Anavekar NS,Rozen WM,Rowe K,Murphy C

    更新日期：2008-06-01 00:00:00

  • Impact of Detection Method and Age on Survival Outcomes in Triple-Negative Breast Cancer: A Population-Based Cohort Analysis.

    abstract：BACKGROUND:Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to exami...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.04.013

    authors： Rayson D,Payne JI,Michael JCR,Tsuruda KM,Abdolell M,Barnes PJ

    更新日期：2018-10-01 00:00:00

  • Development of breast cancer in a 21-year-old childhood Wilms' tumor survivor with a BRCA1 2634delC mutation.

    abstract：:Breast cancer at age 21 is rare, even in individuals who have a genetic predisposition. These early diagnoses are usually the result of a hereditary cancer syndrome. Other contributing factors, such as chemotherapy and radiation for previous malignancies, can also increase the risk of secondary malignancies, including...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2010.11.001

    authors： Dulude AM,D'Souza J,Harrison N,Ramanathan RK

    更新日期：2011-08-01 00:00:00

  • Evaluation of Multifocality and Multicentricity With Breast Magnetic Resonance Imaging in Each Breast Cancer Subtype.

    abstract：INTRODUCTION:The purpose of this study was to evaluate whether diagnostic performance of breast magnetic resonance imaging (MRI) for detection of multifocality and multicentricity (MFMC) of breast cancer (BC) can be influenced by different histotypes or immunophenotypes in newly diagnosed patients with breast cancer. ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.10.012

    authors： Prochowski Iamurri A,Ponziani M,Macchini M,Fogante M,Pistelli M,De Lisa M,Berardi R,Giuseppetti GM

    更新日期：2018-04-01 00:00:00

  • Role of Overweight, Obesity, and Comorbidities in the Prognosis of Patients With Breast Cancer With Brain Metastases.

    abstract：INTRODUCTION:Breast cancer (BC) is the most common cancer in women, and the incidence of brain metastasis (BM) from BC ranges from 20% to 30%, with a median survival of 10 to 15 months. Previous reports have shown that the presence of obesity or diabetes negatively impacts survival. The present study investigates the a...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2018.12.018

    authors： Cacho-Díaz B,Spínola-Maroño H,Reynoso N,González-Aguilar A,Mohar-Betancourt A

    更新日期：2019-04-01 00:00:00

  • Markers of Cardiotoxicity in Early Breast Cancer Patients Treated With a Hypofractionated Schedule: A Prospective Study.

    abstract：PURPOSE:To evaluate, in a series of early breast cancer (BC) patients treated with hypofractionated adjuvant radiotherapy (RT), whether N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I assay measurements can predict acute clinical or preclinical cardiotoxicity. PATI...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.09.005

    authors： De Sanctis V,Alfò M,Vitiello C,Vullo G,Facondo G,Marinelli L,Burocchi S,Gallo G,Valeriani M,Campanella B,Scalabrino G,Russo I,Salerno G,Cardelli P,Osti MF,De Biase L

    更新日期：2020-09-10 00:00:00

  • A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

    abstract：BACKGROUND:Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectom...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2019.02.006

    authors： Landercasper J,Ramirez LD,Borgert AJ,Ahmad HF,Parsons BM,Dietrich LL,Linebarger JH

    更新日期：2019-06-01 00:00:00